Obstructive sleep apnoea (OSA) is characterized by repeated episodes of apnoea and hypopnoea during sleep. Little is known about the potential impact of therapy drugs on the underlying respiratory disorder. Any influence should be taken into account and appropriate action taken, including drug withdrawal if necessary. Here, we review drugs in terms of their possible impact on OSA; drugs which (1) may worsen OSA; (2) are unlikely to have an impact on OSA; (3) those for which data are scarce or contradictory; and (4) drugs with a potentially improving effect. The level of evidence is ranked according to three grades: Arandomized controlled trials (RCTs) with high statistical power; B -RCTs with lower power, non-randomized comparative studies and observational studies; C -retrospective studies and case reports. Our review enabled us to propose clinical recommendations. Briefly, agents worsening OSA or inducing weight gain, that must be avoided, are clearly identified. Drugs such as 'Z drugs' and sodium oxybate should be used with caution as the literature contains conflicting results. Finally, larger trials are needed to clarify the potential positive impact of certain drugs on OSA. In the meantime, some, such as diuretics or other antihypertensive medications, are helpful in reducing OSA-associated cardiovascular morbidity.
Introduction
Obstructive sleep apnoea (OSA) is a common clinical condition characterized by repeated episodes of apnoea and hypopnoea during sleep [6] . Pathophysiological mechanisms are manifold, including compromised pharyngeal anatomy (adipose tissue deposition, local inflammation, rostral fluid shift/oedema) [7] [8] [9] , inadequacy of the upper airway muscles to stiffen/dilate the airway and maintain its patency in response to an increase in ventilatory drive [10, 11] , and, finally, poor upper airway reflexes [12] . The standard therapy of continuous positive airway pressure (CPAP) is efficient in improving OSA and in reducing its associated comorbidities, in compliant patients. Nevertheless, the impact of CPAP when assessed using cardiometabolic biomarkers remains unclear [13] . However, patients often cannot tolerate CPAP, which can produce general discomfort or troublesome nasal symptoms (e.g. congestion, rhinorrhea), leading to poor adherence [14, 15] . Thus, alternative options need to be developed and pharmacological therapies are an obvious approach. However, little is known about the possible influence of commonly used drugs on OSA. The aim of this review was to investigate this field, because any drug having a potential impact on OSA should be evaluated during the workup for OSA in any patient.
In this review we divide drugs into four categories, those which (1) may worsen OSA; (2) are unlikely to have an impact on OSA; (3) for which data are scarce or contradictory; and (4) drugs with a possible positive effect.
We searched the Medline database for all studies mentioning drugs [using International Nonproprietary Names (INN)] and looking at an effect on OSA. Nineteen Medical Subject Headings (MeSH) classes are referenced under 'THER-APEUTIC USES', covering the entire pharmacopoeia, such as 'central nervous system (CNS) agents' or 'respiratory system agents'. Thus, we used the search equations: 'each MeSH class' AND 'OSA' to identify drug class of interest. Then, for each marketed drug, we used the search equations: 'INN' AND 'apnoea/apnea', 'INN' AND 'OSA' and 'INN' AND 'sleep-disordered breathing (SDB)'. Indeed, OSA is by far the most common form of SDB that regroups several chronic conditions in which partial or complete cessation of breathing occurs many times throughout the night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to function and reduces quality of life. We repeated searches until no additional articles were found. No language or date filter was used. Thereby we consider this work as a systematic review. Inclusion criteria were: (i) clinical trial; (ii) evaluation of effect on variables measured by polysomnography (the reference examination for the OSA diagnosis) such as the apnoea-hypopnoea index (AHI), oxygen desaturation index (ODI), respiratory disturbance index, minimum nocturnal oxygen saturation (SaO 2min ) and time spent with an SaO 2 < 90%. The level of evidence was rated using three grades: A -randomized controlled trials (RCTs) (≥20 patients or 10 patients for a cross-over design) and meta-analyses of RCTs; B -RCTs (<20 patients), observational and non-randomized comparative studies; and C -retrospective studies, case reports and comparative studies with biases. We discuss all grade A studies and all the relevant studies we found are included in the tables. Most of the studies we quote are referenced in the Pneumotox database, a website referencing literature of drug-induced respiratory disease (available online at http://www.pneumotox.com/).
Drugs which may worsen OSA
Opioids [16] [17] [18] [19] [20] , benzodiazepines [21] [22] [23] [24] [25] , baclofen [26] [27] [28] , testosterone [29] [30] [31] [32] and drugs inducing weight gain [33] are suspected to worsen sleep apnoea (Table 1) .
Opioids and opiates. Opioids are known CNS respiratory depressants, but the mechanisms responsible for SDB are poorly understood. The opiate respiratory disturbances are mainly due to the activation of the μ-and δ-subtypes of receptor and involve specific types of respiratory-related neurons in the ventrolateral medulla (in particular the PreBötzinger Complex), regulating the respiratory rhythm. Synthetic opiates with affinity for either the μ-or the δ-receptor subtype suppress all parameters of effective breathing. They depress rate and depth of respiration, induce chest and abdominal wall rigidity, reduce upper airway patency and blunt respiratory responsiveness to carbon dioxide and hypoxia [34] . Sleep apnoea induced by opioids is characterized by a combination of obstructive apnoeas and central SDB. Some 75-85% of patients treated by opioids have at least mild sleep apnoea that is severe in 36-41% of cases [10, 11] , depending on the dose [19] . In an RCT that included 19 mild OSA patients, remifentanil for one night induced no change in AHI (the number of obstructive apnoeas decreased and the number of central apnoeas increased), a decrease in SaO 2min and an increase in the total arousal index [20] . Opioids cause relaxation of the tongue and upper airway muscles, which may cause airway obstruction once the patient falls asleep [35] , and the resulting weakness of upper airway muscles may exacerbate OSA. OSA patients receiving opioids such as morphine or fentanyl for chronic management of pain or other symptoms associated with chronic obstructive pulmonary disease or lung cancer may be at risk of adverse effects related to respiratory depression [36, 37] . Long-term opioid therapy seems to induce SDB by increasing the number of central apnoeas and decreasing the number of obstructive apnoeas [38] .
Benzodiazepines.
A Cochrane review has recently investigated the effects of hypnotic and sedative drugs (eszopiclone, zolpidem, flurazepam, temazepam, nitrazepam, triazolam, sodium oxybate and ramelteon) compared to placebo in OSA patients [12] . That review revealed no worsening of OSA (a significant increase in AHI) with any of the studied drugs. However, flurazepam and triazolam significantly lowered nighttime SaO 2 , whereas nitrazepam did not change AHI [22] .
Myorelaxants. Baclofen is a centrally acting gamma aminobutyric acid B agonist prescribed as a muscle relaxant and antispasmodic agent. Despite its usage in the management of alcohol dependence, there is a growing caution concerning baclofen use. Baclofen provokes upper airway collapse during sleep worsening OSA and affecting central apnoeas or hypoventilation during sleep by depressing respiratory drive [26] . Although the negative impact on sleep apnoea awaits further confirmation, it seems prudent to avoid baclofen in OSA patients.
Testosterone. The detrimental effect of testosterone on OSA is consistent with the higher prevalence of OSA in men than in women. In men with no history of sleep apnoea, testosterone increased AHI and prolonged hypoxemia time [29] . Moreover, testosterone worsened SDB, increasing the time spent with an SaO 2 < 90% [31] .
Drugs inducing weight gain. Obesity is the principal risk factor for OSA. About 70% of OSA patients are obese and 40% of the obese have sleep apnoea [39, 40] . There is evidence that systemic inflammatory mediators associated with obesity and the localization of adipose tissue deposits may exacerbate pharyngeal mechanisms that mediate collapsibility and increase susceptibility to OSA [7, 8] . Conversely, OSA may predispose the individual to weight gain [8, 41] . Several medications (atypical antipsychotics in particular, antidepressants, anticonvulsants, antidiabetic drugs, antihistamines, β-and α-adrenergic blockers) are associated with weight gain [33] that can induce or exacerbate OSA. Nevertheless, alternative drugs are available (Table 2 ). For example, weight increase was significantly greater in patients on long-term paroxetine compared to those treated with fluoxetine or sertraline [42] .
Drugs with probably no impact on OSA
For some drugs there is no clear evidence of a positive or negative impact on OSA. This is often because there is only a small number of, or inconclusive, studies, despite mechanisms having been proposed (Table 3) .
Antihypertensive drugs
Angiotensin II receptor blockers. Angiotensin II receptor blockers seem to have a limited impact on OSA. In hypertensive OSA patients the use of valsartan or losartan had no effect on AHI [43, 44] .
Beta-blockers. Beta-blockers seem to have variable effects on OSA [43] [44] [45] [46] , possibly according to the selectivity of their action on adrenoceptor subtypes. Treatment with atenolol or nebivolol had no effect on AHI in hypertensive OSA patients [43, 44] . One study (grade B) reported a reduction in AHI with metoprolol [46] . We found no study that investigated the effects of propranolol on OSA, although the associated weight gain may exacerbate OSA (see section 'Drugs inducing weight gain' above) [33] . Beta blocker safety is reassuring in light of their beneficial effect in coronary artery disease patients.
Calcium channel antagonists. The single RCT investigating the use of mibefradil in OSA reported no change in AHI [47] .
Nicotine. Nicotine is a breathing stimulant that increases muscle activity and dilates the upper airway. The use of nicotine gum at bedtime was reported to prevent OSA in the first 2 h of sleep [48] , although two subsequent RCTs concluded that nicotine had no effect on AHI [49, 50] .
Anaesthetic agents. OSA has become a major concern for anaesthetists [51, 52] . A systematic review highlighted AHI, apnoea hypopnoea index; BMI, body mass index; im, intramuscular; OSA, obstructive sleep apnoea; RCT, randomized controlled trial; RDI, respiratory disturbance index; SaO adverse effects of the currently available anaesthetics and in patients with known OSA undergoing elective surgery [53, 54] . Propofol administered along with isoflurane decreased ODI in the immediate postoperative period [55] . However, an RCT with propofol, desflurane, and remifentanil reported no change in ODI in OSA patients [56] . There are few studies assessing the effect of anaesthesia on the patency of the upper airway in patients with OSA and they rarely compare agents; however, the impact is probably marginal [55] [56] [57] [58] [59] [60] [61] [62] .
Melatonin-related drugs. Two RCTs concluded that ramelteon, a melatonin receptor agonist used for the treatment of insomnia had no effect on the number of central, obstructive or mixed apnoea episodes in OSA patients [63, 64] .
Drugs that induce weight loss. The effects of drugs that induce weight loss on OSA are summarized in Table 4 . In particular, carbonic anhydrase inhibitors improve OSA by promoting ventilation via chemosensory mechanisms [65] and have an indirect effect on obese patients through weight loss. Many molecules for weight reduction are in development. Nevertheless, it should be remembered that pharmacological approaches to weight loss have a limited effect (10% weight loss is rarely achieved), a rebound effect when stopped (with subsequent weight gain) and serious safety concerns. Indeed, weight regulation is highly complex and involves numerous metabolic mechanisms. A pharmacological strategy alone probably has hardly any impact. Antiepileptic drugs. In obese patients with moderate to severe OSA, a combination of topiramate and phentermine decreased AHI correlated to weight loss [66] . Multifactorial causes, including weight loss, but also changes in serum bicarbonate concentration and pH, may account for the beneficial effects of topiramate on OSA [67] . In overweight/obese OSA patients zonisamide decreased AHI and ODI, but was less effective than CPAP treatment [68] .
Thyroid hormone. The weight loss induced by thyroid hormone replacement therapy [69] and the link between hypothyroidism and OSA [70, 71] would suggest that thyroid hormone can slightly improve OSA [72] [73] [74] .
Other drugs. Ondansetron [75] , clonidine [76] and almitrine [77] appear to induce no change in AHI, but larger studies are needed.
Drugs with an unresolved impact on OSA Table 5 lists drugs whose impact on OSA needs to be clarified.
'Z' drugs (eszopiclone and zolpidem). 'Z' drugs are a group of non-benzodiazepine drugs with effects similar to benzodiazepines (gamma aminobutyric acid agonist), and most of whose names start with the letter 'Z'. Surprisingly, some CNS depressants (sedatives and tranquilizers) such as 'Z' drugs might improve SDB by raising the low respiratory arousal threshold observed in OSA patients. While zolpidem did not change AHI, it significantly lowered SaO 2min [21, [78] [79] [80] . Drugs used to treat acromegaly. Some studies report a high prevalence of OSA in patients with acromegaly. In theory, acromegaly treatments such as growth hormone could improve OSA by lowering the body mass index. However, these treatments seem to have no impact on OSA. Larger studies are needed as no grade A study exists [87] [88] [89] .
Angiotensin-converting enzyme inhibitors (ACEI). ACEI may exacerbate OSA, particularly in patients who develop cough and/or symptoms of rhinopharyngeal inflammation or upper airway collapse [90] . While cilazapril treatment did not modify AHI [91] , a significant decrease in AHI was observed after withdrawal of ACEI (enalapril, perindopril or ramipril) in nine OSA patients presenting with coughs [92] . These results suggest that ACEI can contribute to OSA, particularly in patients with adverse effects of the drugs such as cough and/or upper airway disorders. A therapeutic switch should be considered for such patients.
Sabeluzole. Hypoxaemia stimulates glutamate release in the CNS and is a characteristic of SDB. In turn, glutamate can elicit apnoea via its action on N-methyl-D-aspartate (NMDA) receptors. Sabeluzole, a glutamate antagonist, decreased the ODI, and increased SaO 2min in a dose-dependent manner [93] . However, in a later study by the same group, no change in AHI or oxygen saturation was found after the administration of an NMDA receptor antagonist [94] .
Antidepressant drugs. Paroxetine led to a decrease in AHI during NREM sleep, but not during REM sleep [95] and not change AHI in a grade B study [96] . Fluoxetine and protriptyline seem to decrease AHI, but it is still controversial [97] [98] [99] [100] .
In contrast, mirtazapine did not improve sleep apnoea [101] . However, as mirtazapine causes weight gain, it can worsen OSA. Gain in weight had been reported with mirtazapine by Carley et al. [102] , but they found a decrease in AHI as reported in a case report [103] . Trazodone in a small RCT increased arousals [104] . TNF-α antagonists. Inflammation is a mechanism shared by sleep apnoea, insulin resistance and visceral obesity, promoting atherosclerosis, cardiovascular diseases and premature death [105] . Pro-inflammatory cytokines, tumour necrosis factor-α (TNF-α) and interleukin-6 are elevated in OSA and have been proposed as mediators of excessive daytime sleepiness and fatigue [106, 107] . Numerous studies investigating the effect of anti-inflammatory drugs on OSA have been reported, but the results are sometimes contradictory and the situation needs to be clarified. TNF-α antagonists are prescribed for rheumatoid arthritis, inflammatory bowel diseases and psoriasis; and OSA is frequently found in patients with these inflammatory diseases [108, 109] . The only grade A RCT included OSA patients with psoriasis who were treated with adalimumab, but they showed no improvement in OSA [109] . The effect of etanercept and infliximab are controversial [106, 110, 111] ; however, according to the available data [106, 109] , etanercept and adalimumab should be preferred to infliximab for OSA patients.
Proton pump inhibitors. Only B grade studies have investigated the effect of proton pump inhibitors on OSA [112] [113] [114] [115] [116] [117] [118] .
Drugs with a possible positive impact on OSA Anti-inflammatory drugs. Contrary to TNF-α antagonists, overall, the data are in favour of the use of antileukotrienes and nasal corticosteroids in OSA patients (Table 6 ) unlike prednisone [119] .
Antileukotrienes. High levels of leukotrienes are found in the respiratory systems of children with OSA. An RCT found that montelukast, a leukotriene receptor antagonist, improved respiratory disturbance and decreased AHI in children [120] . Nasal corticosteroids. Increased resistance to nasal airflow can contribute to the obstruction of upper airways during sleep. Nasal corticosteroids may have a beneficial effect, particularly in patients with snoring or rhinitis and diagnosed or suspected OSA. Fluticasone nasal spray improves OSA in children [121] and has been shown to reduce the AHI in adults that is correlated with an improvement in nasal airflow resistance [122] . In the same way, intranasal budesonide reduced the severity of OSA (improving SaO 2min and AHI) in children [123, 124] . Finally, treatment with mometasone [125, 126] or the intranasal decongestant vasoconstrictor xylometazoline reduced AHI [127] , whereas another nasal decongestant did not [129] .
Topical soft tissue lubricant. These molecules seem to decrease AHI [129, 130] .
Diuretics. Upper airway collapse caused by pharyngeal oedema can contribute to SDB, particularly in obese and hypertensive OSA patients. Indeed, during the day, due to gravity excess fluid collects in the lower extremities that is redistributed rostrally to the neck on lying down at night, and may increase upper airway collapsibility [9] . To date, no grade A study has been carried out, but furosemide, spironolactone and acetazolamide seem to have a positive effect on OSA [99, [131] [132] [133] [134] [135] . Acetazolamide resulted in a significantly reduced loop gain associated with a 51% improvement in AHI [133] and reduced OSA severity [99, 134] , probably by reducing the sensitivity of the ventilatory control system. However, it does not reduce upper airway collapsibility or raise the arousal threshold. Nevertheless, acetazolamide increased resting ventilation and attenuated hyperventilation following arousal bỹ 2.5-fold in OSA patients [135] . This suggests an additional mechanism through which this drug contributes to improving OSA.
Beta-2 agonists. Studies investigating bronchodilators used in asthma such as theophylline and salmeterol have given inconsistent results in OSA patients. Almost all studies with theophylline reported a decrease in AHI [136] [137] [138] [139] [140] [141] , whereas no change was observed with aminophylline [142] or salmeterol [143] .
Acetylcholinesterase inhibitors. While acetylcholinesterase inhibitors enhance cholinergic transmission, the mechanism affecting ventilation in OSA is unknown. The cholinergic system plays a role in the regulation of breathing during sleep and in reducing the collapsibility of upper airways. However, the improvement in oxygen saturation parameters is partly due to increased chemosensitivity, leading to respiratory instability and possibly to increased AHI in individuals with high loop gain. Physostigmine was found to reduce AHI (particularly during REM sleep) and increase SaO 2 [144] . Donepezil decreased AHI [145, 146] , but a single dose did not [147] .
Female hormones. Oestrogen replacement therapy had no effect on partial airway obstruction, although it decreased the occurrence and frequency of sleep apnoea in women [148, 149] . Women on hormone replacement therapy had a lower occurrence of SDB than untreated ones [150] . The lower prevalence of OSA in women than in men and the increase in incidence during the menopausal period are in line with this beneficial effect [151] . Medroxyprogesterone led to a small improvement in AHI in postmenopausal women with mild SDB [152] . However, a later study found that while it increases ventilatory responses, it induces no change in AHI [153] contrary to cases reported by Strohl et al. [154] .
Anti-Parkinson's disease medications. The prevalence of OSA among patients with Parkinson's disease is still controversial. A meta-analysis on 322 parkinsonian patients concluded that these patients have a lower risk of OSA compared to the general population [155] . In contrast, recent studies showed increased prevalence of OSA in Parkinson's disease patients. Studies on drug-naïve parkinsonian patients have shown that around 45% of patients had abnormal AHI and that OSA was frequent [156, 157] . It seems that extrapyramidal involvement of the striated upper airway musculature may limit airflow and cause respiratory deficiency. However, anti-Parkinson's drugs seem to decrease AHI [158, 159] .
Treatment with medical gases. Carbon dioxide (CO 2 ) inhalation stabilizes arterial CO 2 levels and eliminates hypocapnia-induced hypopnoea and periodic breathing [160] . CO 2 stimulated upper airway inspiratory muscle tonic activity relative to chest wall inspiratory muscle activity and reduced apnoea time [161] . A reduction in AHI was reported in OSA men, without change in the arousal index [162] . Two case studies showed beneficial effects of CO 2 on OSA [163, 164] . Supplemental oxygen (transtracheal or inhaled) reduced AHI, raised SaO 2min and improved subjective symptoms of sleepiness [38, 165, 166] . However, while oxygen reduced central and mixed apnoeas, obstructive apnoea increased [167] . Finally, oxygen therapy increased SaO 2min and reduced sleepiness in OSA patients, although their respiratory disturbance index was unchanged [168] .
Conclusion
We found many studies evaluating the effects of pharmacological agents on OSA. As shown by Kohler et al. [169] , there are some limitations to some of these studies. Those graded B or C (reported only in tables) have a lack of statistical power, including too few patients, with heterogeneity of the studied population. There is a lack of consensus on the best variable (AHI, ODI, SAO 2 , sleepiness or other) for the classification of OSA severity, which renders it difficult to draw clear conclusions. This review clearly identified drugs exacerbating OSA that should be avoided (i.e. opiates, benzodiazepines, baclofen or drugs associated with weight gain), based on robust RCTs (grade A studies). Many other drugs for which different studies have given contradictory results (such as 'Z drugs' and sodium oxybate) need to be used with caution. Finally, larger trials are needed to clarify the potential of drugs with a possible positive impact on OSA: anti-inflammatory drugs, diuretics or beta-2 agonists. In the meantime, some, such as antihypertensive medications, are clearly useful for reducing the cardiovascular risk posed by OSA. Finally, further pharmacological analysis comparing drugs of the same class and indicating similarity and differences of their effects on OSA should be useful.
